Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas: A Multi-centre Phase I and II Study.

Trial Profile

Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas: A Multi-centre Phase I and II Study.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Alemtuzumab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
  • Indications T cell lymphoma
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms ACCAPELA
  • Most Recent Events

    • 24 Nov 2015 Last checked against ClinicalTrials.gov record (NCT00363090).
    • 24 Nov 2015 Last checked against ClinicalTrials.gov record (NCT00363090).
    • 02 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top